PL3578266T3 - Formulacja octanu abirateronu - Google Patents

Formulacja octanu abirateronu

Info

Publication number
PL3578266T3
PL3578266T3 PL19173089.4T PL19173089T PL3578266T3 PL 3578266 T3 PL3578266 T3 PL 3578266T3 PL 19173089 T PL19173089 T PL 19173089T PL 3578266 T3 PL3578266 T3 PL 3578266T3
Authority
PL
Poland
Prior art keywords
acetate formulation
abirateron
abirateron acetate
formulation
acetate
Prior art date
Application number
PL19173089.4T
Other languages
English (en)
Inventor
William H. Bosch
Marck Norret
Paul NEMETH
Matt Callahan
Original Assignee
Sun Pharmaceutical Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Limited filed Critical Sun Pharmaceutical Industries Limited
Publication of PL3578266T3 publication Critical patent/PL3578266T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C19/00—Other disintegrating devices or methods
    • B02C19/16—Mills provided with vibrators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL19173089.4T 2013-03-15 2014-03-17 Formulacja octanu abirateronu PL3578266T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361789141P 2013-03-15 2013-03-15
US201361883941P 2013-09-27 2013-09-27

Publications (1)

Publication Number Publication Date
PL3578266T3 true PL3578266T3 (pl) 2024-10-21

Family

ID=51538105

Family Applications (2)

Application Number Title Priority Date Filing Date
PL19173089.4T PL3578266T3 (pl) 2013-03-15 2014-03-17 Formulacja octanu abirateronu
PL14765788T PL2969227T3 (pl) 2013-03-15 2014-03-17 Formulacja octanu abirateronu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14765788T PL2969227T3 (pl) 2013-03-15 2014-03-17 Formulacja octanu abirateronu

Country Status (20)

Country Link
US (3) US20140287039A1 (pl)
EP (2) EP2969227B1 (pl)
JP (4) JP2016514707A (pl)
KR (3) KR20180021932A (pl)
CN (2) CN105246598B (pl)
AU (2) AU2014232508C1 (pl)
BR (1) BR112015023629A8 (pl)
CA (1) CA2907415C (pl)
CL (1) CL2015002787A1 (pl)
ES (2) ES2986853T3 (pl)
HK (1) HK1219457A1 (pl)
IL (1) IL241612B (pl)
MX (1) MX2015013247A (pl)
NZ (1) NZ712350A (pl)
PL (2) PL3578266T3 (pl)
RU (1) RU2732136C2 (pl)
SG (2) SG10201709400VA (pl)
TW (2) TWI686212B (pl)
WO (1) WO2014145813A1 (pl)
ZA (1) ZA201507209B (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2856316C (en) 2011-10-28 2020-07-28 Global Dynamics Incorporated Steerable fairing string
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
EP3080141A1 (en) * 2013-12-12 2016-10-19 Basf Se Solid form of abiraterone acetate
WO2015114314A1 (en) * 2014-01-28 2015-08-06 Cipla Limited Pharmaceutical composition comprising abiraterone
WO2016044701A1 (en) * 2014-09-18 2016-03-24 Iceutica Inc. Abiraterone acetate formulation and methods of use
CN105616364B (zh) * 2014-11-07 2018-11-02 深圳万乐药业有限公司 醋酸阿比特龙片及其制备方法
RS62421B1 (sr) 2014-12-05 2021-10-29 Aragon Pharmaceuticals Inc Anti-kancerogeni sastavi
CN114886852A (zh) 2014-12-05 2022-08-12 阿拉贡药品公司 抗癌组合物
HUP1500055A1 (hu) 2015-02-09 2016-08-29 Druggability Technologies Ip Holdco Ltd Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények
EP3824908A1 (en) * 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
CN108697700B (zh) 2016-02-04 2021-08-17 辛多美制药有限公司 氘代多潘立酮组合物和用于治疗病症的方法
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
MX2018009866A (es) 2016-02-16 2018-11-09 Gx Tech Canada Ltd Depresor de aleta sustentadora de cinta.
EA201892828A1 (ru) * 2016-06-03 2019-05-31 Арагон Фармасьютикалз, Инк. Противораковые композиции
CA3061267A1 (en) * 2017-04-07 2018-10-11 Maa Laboratories, Inc. Methods of improving the solubility and bioavailability of therapeutic agents
US12478612B2 (en) 2017-06-30 2025-11-25 Cindome Pharma, Inc. Deuterated domperidone compositions, methods, and preparation
MA50189A (fr) * 2017-09-22 2021-05-19 Dispersol Technologies Llc Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci
WO2019186444A1 (en) * 2018-03-29 2019-10-03 Leiutis Pharmaceuticals Pvt, Ltd Oral liquid formulations of abiraterone
PL3826770T3 (pl) * 2018-07-24 2024-10-28 Camx Power, L.L.C. Dodatek do mielenia na sucho oraz sposób
SG11202100823RA (en) 2018-07-31 2021-02-25 Microbion Corp Bismuth-thiol compositions and methods of use
WO2020028561A1 (en) 2018-07-31 2020-02-06 Microbion Corporation Bismuth-thiol compositions and methods for treating wounds
HU231297B1 (hu) * 2018-07-31 2022-09-28 Richter Gedeon Nyrt Stabil gyógyszerkészítmények és eljárás az előállításukra
US11077920B2 (en) 2018-10-09 2021-08-03 Ion Geophysical Corporation Modular foil system for towed marine array
JP2022523704A (ja) * 2019-01-25 2022-04-26 シェンチェン・ファーマシン・カンパニー・リミテッド 医薬組成物
CN114026106B (zh) 2019-03-06 2025-01-21 普洛拉治疗公司 阿比特龙前药
CN113825514A (zh) * 2019-03-18 2021-12-21 分散技术有限责任公司 阿比特龙-环状寡聚体药物制剂及其形成和施用方法
CN110538150A (zh) 2019-09-26 2019-12-06 湖南瑞林医药科技有限公司 一种含有醋酸阿比特龙的药物组合物及其制备方法和应用
US20210113557A1 (en) * 2019-10-22 2021-04-22 Arvinas Operations, Inc. Methods of treating prostate cancer
CN113133983B (zh) * 2020-01-20 2023-12-12 鲁南制药集团股份有限公司 一种治疗前列腺癌的药物组合物
US20230158047A1 (en) * 2020-04-16 2023-05-25 Tavanta Therapeutics Hungary Incorporated Methods and compositions for treating prostate cancer
US12103056B2 (en) 2020-05-07 2024-10-01 Nanchang University Organic waste collection apparatus and method
EP3944860A1 (en) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
CN112933053B (zh) * 2021-01-29 2022-11-25 中国药科大学 一种醋酸阿比特龙的纳米晶体及其制剂和制备方法
CN117120034A (zh) 2021-02-15 2023-11-24 普洛佩拉治疗公司 阿比特龙前药
US11801252B2 (en) * 2021-03-05 2023-10-31 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition
KR20240012436A (ko) * 2021-05-25 2024-01-29 액티브 바이오테크 에이비 복수의 타스퀴니모드 입자 및 그 용도
TWI828471B (zh) 2021-12-15 2024-01-01 大陸商湖南慧澤生物醫藥科技有限公司 醋酸阿比特龍的自微乳組合物和應用
KR20240010280A (ko) 2022-07-15 2024-01-23 한미약품 주식회사 아비라테론 아세테이트 또는 이의 약제학적으로 허용 가능한 염을 포함하는 약제학적 조성물
WO2025163665A1 (en) * 2024-01-29 2025-08-07 Dr. Reddy’S Laboratories Limited Stable pharmaceutical compositions of abiraterone

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478705A (en) 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
US5500331A (en) 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
US20050215472A1 (en) * 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
NZ573823A (en) * 2006-06-30 2012-05-25 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
HRP20130961T1 (hr) * 2006-08-25 2013-11-22 Janssen Oncology, Inc. Kombinacije za tretman raka
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
CA2697150A1 (en) * 2007-08-17 2009-02-26 Teva Pharmaceutical Industries Ltd. Methods and compositions for controlling the bioavailability of poorly soluble drugs
NZ710384A (en) * 2009-04-24 2017-03-31 Iceutica Pty Ltd A novel formulation of indomethacin
KR20160148041A (ko) * 2009-04-24 2016-12-23 아이슈티카 피티와이 리미티드 캅셀화된 나노입자의 상업적 규모의 생산
CA2759123C (en) * 2009-04-24 2019-01-15 Iceutica Pty Ltd Compositions of diclofenac acid with improved dissolution
CA2759109A1 (en) * 2009-04-24 2010-10-28 Iceutica Pty Ltd A solid dosage form of ciprofloxacin having small particle size and improved powder handling characteristics
HRP20201241T1 (hr) * 2011-04-15 2020-11-27 Janssen Pharmaceutica N.V. Nanosuspenzije lijeka osušene zamrzavanjem
JP2014523445A (ja) * 2011-07-18 2014-09-11 トーカイ ファーマシューティカルズ,インク. 前立腺癌を処置するための新規な組成物及び方法
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
CN102743393A (zh) * 2012-07-27 2012-10-24 海南盛科生命科学研究院 一种含有醋酸阿比特龙的药物组合物及制备工艺
WO2014083512A1 (en) * 2012-11-28 2014-06-05 Dr. Reddy's Laboratories Limited Process for preparation of abiraterone acetate

Also Published As

Publication number Publication date
SG11201507681PA (en) 2015-10-29
CN105246598B (zh) 2019-09-13
BR112015023629A2 (pt) 2017-07-18
AU2018241103B2 (en) 2020-08-13
EP2969227A1 (en) 2016-01-20
ZA201507209B (en) 2016-12-21
CA2907415A1 (en) 2014-09-18
KR20190141270A (ko) 2019-12-23
TWI731321B (zh) 2021-06-21
RU2732136C2 (ru) 2020-09-11
AU2014232508A1 (en) 2015-10-08
KR102121404B1 (ko) 2020-06-11
CA2907415C (en) 2022-04-05
MX2015013247A (es) 2016-11-25
WO2014145813A1 (en) 2014-09-18
PL2969227T3 (pl) 2019-12-31
TWI686212B (zh) 2020-03-01
SG10201709400VA (en) 2018-01-30
NZ712350A (en) 2020-08-28
JP2021008521A (ja) 2021-01-28
TW201513896A (zh) 2015-04-16
CN110604721B (zh) 2022-02-08
AU2014232508C1 (en) 2023-01-19
AU2018241103A1 (en) 2018-10-25
KR20160023641A (ko) 2016-03-03
RU2015144285A (ru) 2017-04-24
US20160067265A1 (en) 2016-03-10
KR20180021932A (ko) 2018-03-05
HK1219457A1 (zh) 2017-04-07
EP3578266B1 (en) 2024-06-19
EP2969227B1 (en) 2019-05-08
TW201943408A (zh) 2019-11-16
JP2018135351A (ja) 2018-08-30
JP2016514707A (ja) 2016-05-23
HK1220162A1 (en) 2017-04-28
CN105246598A (zh) 2016-01-13
ES2741800T3 (es) 2020-02-12
AU2014232508B2 (en) 2018-07-12
BR112015023629A8 (pt) 2023-04-11
EP3578266A1 (en) 2019-12-11
JP7320485B2 (ja) 2023-08-03
US20170354665A1 (en) 2017-12-14
CN110604721A (zh) 2019-12-24
CL2015002787A1 (es) 2016-05-13
JP7752150B2 (ja) 2025-10-09
EP2969227A4 (en) 2016-12-07
IL241612B (en) 2020-03-31
US20140287039A1 (en) 2014-09-25
ES2986853T3 (es) 2024-11-13
JP2023103410A (ja) 2023-07-26

Similar Documents

Publication Publication Date Title
FIC20240001I1 (fi) Tislelitsumabi
NL301222I2 (nl) valoctocogene roxaparvovec
NO2023037I1 (no) Mirikizumab
EP3065716C0 (en) FORMULATIONS
DK3342773T3 (da) Syk-hæmmere
DK3613453T3 (da) Fordamper
HRP20181334T1 (hr) Samohodno plovilo
HUE037097T2 (hu) Hõszigetelõpanel
DK3077047T3 (da) Aramcholsalte
DK3052081T3 (da) Pastil
DK3060460T3 (da) Saddel
DK2956698T3 (da) Bindestrimler
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
EP2943489A4 (en) DEUTERATED MOMELOTINIB
PL2945641T3 (pl) Cykloalkinowe pochodne sacharydów
DK2946640T3 (da) Langmuir-probe
DE102013106534B8 (de) Chromatographiepipettenspitze
EP2991647A4 (en) DEUTERED AMLEXANOX
EP2970310A4 (en) 5-BROMO-indirubins
EP2853297A4 (en) kendama
DK3071227T3 (da) Fiskevaccine
HUE050917T2 (hu) Hidrokortizon-tartalmú készítmény
DE112014001252A5 (de) Aufbissschiene
DK3086679T3 (da) Sportssko
DK2981168T3 (da) Laminitiskile